U.S. Government Purchases Additional 200 Million Doses of Moderna’s COVID-19 Vaccine
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has purchased an additional 200 million doses of Modernas COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Modernas pipeline.
- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has purchased an additional 200 million doses of Modernas COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Modernas pipeline.
- As of June 14, Moderna has supplied 217 million released doses of the vaccine to the U.S. government.
- The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein.
- Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine.